Dyadic achieves milestone payments, advances commercial focus, revenue growth.

• Dyadic International, a biotech company, achieves milestone payments in collaborations. • Proliant Health & Biologicals in life sciences and Inzymes ApS in food & nutrition. • Dyadic transforms into a commercially focused, revenue-driven company. • Joe Hazelton, Dyadic President & COO, highlights progress in partnerships.

Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, has announced significant milestone payments in its collaborations with Proliant Health & Biologicals in life sciences and Inzymes ApS in food and nutrition. The company, which produces precision-engineered, animal-free proteins and enzymes, has been making strides towards its transformation into a commercially focused, revenue-driven entity.

Joe Hazelton, Dyadic's President and Chief Operating Officer, highlighted the progress made in the third quarter, noting substantial achievements in partnerships with Proliant Health and Biologicals in the life sciences sector, as well as ongoing collaborations with Inzymes in food and nutrition. These milestones underscore the versatility and scalability of Dyadic’s protein production platforms across multiple markets.

Dyadic's proprietary microbial platforms, such as the C1 and Dapibus™ expression systems, support flexible and cost-effective manufacturing. These systems are the foundation of a growing portfolio of commercial and partnered programs, enabling customers to develop more efficient, scalable, and sustainable products.

The company's focus on capitalizing on near-term commercialization opportunities is bolstered by a stronger balance sheet and an expanding pipeline of both partner-led and internally developed products. Dyadic remains committed to leveraging its technology to meet the growing demand for high-quality proteins in various industries.

For more information about Dyadic, please visit www.dyadic.com.